Literature DB >> 18474932

Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD.

Kenneth D Gadow1, Edith E Nolan, Jeffrey Sverd, Joyce Sprafkin, Jayne Schneider.   

Abstract

Our primary objective was to determine if immediate-release methylphenidate is an effective treatment for oppositional defiant disorder diagnosed from mother's report in children with both chronic multiple tic disorder and attention-deficit hyperactivity disorder (ADHD). Children (n = 31) aged 6 to 12 years received placebo and 3 doses of methylphenidate twice daily for 2 weeks each under double-blind conditions and were assessed with ratings scales and laboratory measures. Results indicated significant improvement in both oppositional and ADHD behaviors with medication; however, the magnitude of treatment effect varied considerably as a function of disorder (ADHD > Oppositional behaviors), informant (teacher > mother), assessment instrument, and specific oppositional behavior (rebellious > disobeys rules). Drug response was comparable with that in children (n = 26) who did not have diagnosed oppositional defiant disorder, but comorbidity appeared to alter the perceived benefits for ADHD according to mother's report. Methylphenidate is an effective short-term treatment for oppositional behavior in children with comorbid ADHD and chronic multiple tic disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474932     DOI: 10.1177/0883073808315412

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  16 in total

1.  Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.

Authors:  Kenneth D Gadow; L Eugene Arnold; Brooke S G Molina; Robert L Findling; Oscar G Bukstein; Nicole V Brown; Nora K McNamara; E Victoria Rundberg-Rivera; Xiaobai Li; Heidi L Kipp; Jayne Schneider; Cristan A Farmer; Jennifer L Baker; Joyce Sprafkin; Robert R Rice; Srihari S Bangalore; Eric M Butter; Kristin A Buchan-Page; Elizabeth A Hurt; Adrienne B Austin; Sabrina N Grondhuis; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-06-12       Impact factor: 8.829

2.  Deconstructing oppositional defiant disorder: clinic-based evidence for an anger/irritability phenotype.

Authors:  Deborah A G Drabick; Kenneth D Gadow
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2012-03-03       Impact factor: 8.829

Review 3.  Prevention of serious conduct problems in youth with attention deficit/hyperactivity disorder.

Authors:  Miguel T Villodas; Linda J Pfiffner; Keith McBurnett
Journal:  Expert Rev Neurother       Date:  2012-10       Impact factor: 4.618

4.  Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial.

Authors:  Kenneth D Gadow; Nicole V Brown; L Eugene Arnold; Kristin A Buchan-Page; Oscar G Bukstein; Eric Butter; Cristan A Farmer; Robert L Findling; David J Kolko; Brooke S G Molina; Robert R Rice; Jayne Schneider; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2016-04-13       Impact factor: 8.829

5.  Symptoms of autism and schizophrenia spectrum disorders in clinically referred youth with oppositional defiant disorder.

Authors:  Kenneth D Gadow; Deborah A G Drabick
Journal:  Res Dev Disabil       Date:  2012-03-22

6.  Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder.

Authors:  Peter M Wehmeier; Alexander Schacht; Ralf W Dittmann; Karin Helsberg; Christian Schneider-Fresenius; Martin Lehmann; Monika Bullinger; Ulrike Ravens-Sieberer
Journal:  Qual Life Res       Date:  2010-12-07       Impact factor: 4.147

7.  The efficiency of behavior rating scales to assess inattentive-overactive and oppositional-defiant behaviors: applying generalizability theory to streamline assessment.

Authors:  Robert J Volpe; Amy M Briesch; Kenneth D Gadow
Journal:  J Sch Psychol       Date:  2010-10-16

8.  Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.

Authors:  Daniel F Connor; Robert L Findling; Scott H Kollins; Floyd Sallee; Frank A López; Andrew Lyne; Gerald Tremblay
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

9.  The relationship between ADHD symptom dimensions, clinical correlates, and functional impairments.

Authors:  Annie A Garner; Briannon C Oʼconnor; Megan E Narad; Leanne Tamm; John Simon; Jeffery N Epstein
Journal:  J Dev Behav Pediatr       Date:  2013-09       Impact factor: 2.225

10.  Pharmacological Management of Pediatric Patients with Comorbid Attention-Deficit Hyperactivity Disorder Oppositional Defiant Disorder.

Authors:  Daniel F Connor
Journal:  Paediatr Drugs       Date:  2015-10       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.